NCT06205849 — University of California, San Diego cancer immunotherapy trial
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
Registry record
| Registry ID | NCT06205849 ↗ |
|---|---|
| Lead sponsor | University of California, San Diego |
| Collaborators | University of California, Los Angeles, National Cancer Institute (NCI) |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Pancreatic Cancer |
| Enrollment | 18 participants (target) |
| Start date | 2024-07-17 |
| Primary completion | 2028-08 (est.) |
| Last registry update | 25 Jun 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06205849), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06205849?
NCT06205849 (Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by University of California, San Diego.
Is NCT06205849 recruiting?
As of the 2026-06-25 registry update, NCT06205849 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06205849?
The lead sponsor is University of California, San Diego. Collaborators: University of California, Los Angeles, National Cancer Institute (NCI).
What condition does NCT06205849 study?
The registered condition is Pancreatic Cancer. Primary completion is listed as 2028-08 (estimated).
Are results available for NCT06205849?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06205849.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.